• Progress in Medical Physics
• /
• v.31 no.3
• /
• pp.54-62
• /
• 2020

Dose calculation algorithms play an important role in radiation therapy and are even the basis for optimizing treatment plans, an important feature in the development of complex treatment technologies such as intensity-modulated radiation therapy. We reviewed the past and current status of dose calculation algorithms used in the treatment planning system for radiation therapy. The radiation-calculating dose calculation algorithm can be broadly classified into three main groups based on the mechanisms used: (1) factor-based, (2) model-based, and (3) principle-based. Factor-based algorithms are a type of empirical dose calculation that interpolates or extrapolates the dose in some basic measurements. Model-based algorithms, represented by the pencil beam convolution, analytical anisotropic, and collapse cone convolution algorithms, use a simplified physical process by using a convolution equation that convolutes the primary photon energy fluence with a kernel. Model-based algorithms allowing side scattering when beams are transmitted to the heterogeneous media provide more precise dose calculation results than correction-based algorithms. Principle-based algorithms, represented by Monte Carlo dose calculations, simulate all real physical processes involving beam particles during transportation; therefore, dose calculations are accurate but time consuming. For approximately 70 years, through the development of dose calculation algorithms and computing technology, the accuracy of dose calculation seems close to our clinical needs. Next-generation dose calculation algorithms are expected to include biologically equivalent doses or biologically effective doses, and doctors expect to be able to use them to improve the quality of treatment in the near future.

• Communications for Statistical Applications and Methods
• /
• v.29 no.4
• /
• pp.421-439
• /
• 2022

Phase I dose-finding trials are essential in drug development. By finding the maximum tolerated dose (MTD) of a new drug or treatment, a Phase I trial establishes the recommended doses for later-phase testing. The primary toxicity endpoint of interest is often a binary variable, which describes an event of a patient who experiences dose-limiting toxicity. However, there is a growing interest in dose-finding studies regarding non-binary outcomes, defined by either the weighted sum of rates of various toxicity grades or a continuous outcome. Although several novel methods have been proposed in the literature, accessible software is still lacking to implement these methods. This study introduces a newly developed R package, UnifiedDoseFinding, which implements three phase I dose-finding methods with non-binary outcomes (Quasi- and Robust Quasi-CRM designs by Yuan et al. (2007) and Pan et al. (2014), gBOIN design by Mu et al. (2019), and by a method by Ivanova and Kim (2009)). For each of the methods, UnifiedDoseFinding provides corresponding functions that begin with next that determines the dose for the next cohort of patients, select, which selects the MTD defined by the non-binary toxicity endpoint when the trial is completed, and get oc, which obtains the operating characteristics. Three real examples are provided to help practitioners use these methods. The R package UnifiedDoseFinding, which is accessible in R CRAN, provides a user-friendly tool to facilitate the implementation of innovative dose-finding studies with nonbinary outcomes.

• Journal of Radiation Protection and Research
• /
• v.47 no.2
• /
• pp.77-85
• /
• 2022

Background: After the Fukushima Daiichi Nuclear Power Station (FDNPS) accident, a model was developed to estimate the external exposure doses for residents who were expected to return to their homes after evacuation orders were lifted. However, the model's accuracy and uncertainties in parameters used to estimate external doses have not been evaluated. Materials and Methods: The model estimates effective doses based on the integrated ambient dose equivalent (H^*(10)) and life patterns, considering a dose reduction factor to estimate the indoor H^*(10) and a conversion factor from H^*(10) to the effective dose. Because personal dose equivalent (H_p(10)) has been reported to agree well with the effective dose after the FDNPS accident, this study validates the model's accuracy by comparing the estimated effective doses with H_p(10). The H_p(10) and life pattern data were collected for 36 adult participants who lived or worked near the FDNPS in 2019. Results and Discussion: The estimated effective doses correlated significantly with H_p(10); however, the estimated effective doses were lower than H_p(10) for indoor sites. A comparison with the measured indoor H^*(10) showed that the estimated indoor H^*(10) was not underestimated. However, the H_p(10) to H^*(10) ratio indoors, which corresponds to the practical conversion factor from H^*(10) to the effective dose, was significantly larger than the same ratio outdoors, meaning that the conversion factor of 0.6 is not appropriate for indoors due to the changes in irradiation geometry and gamma spectra. This could have led to a lower effective dose than H_p(10). Conclusion: The estimated effective doses correlated significantly with H_p(10), demonstrating the model's applicability for effective dose estimation. However, the lower value of the effective dose indoors could be because the conversion factor did not reflect the actual environment.

• The Korea Journal of Herbology
• /
• v.34 no.1
• /
• pp.43-50
• /
• 2019

Objectives : The purpose of this study was to proofread 'one ryang' in the Decoction of ${\ll}$Treatise on Cold Damage Diseases${\gg}$. Methods : I found out the ratio of maximum dose and minimum dose in this book. On the basis of the ratio, I corrected 'one ryang' in diverse decoctions. Results : In any decoction, maximum dose of medicinal medica in one decoction could not exceed four times minimum dose. Specifically, in the case that maximum dose in one decoction is sixteen ryang, it could not exceed eight times minimum dose in the same decoction. Any medicinal medica used in two decoctions or more, its maximum dose could not exceed four times minimum dose in other decoctions. On the basis of these results, it should be changed into three ryangs that are one ryang dose of 'Haematitum' of Seonbokdaeja Tang, 'Ginger' of Bujageongang Tang, Baektong Tang, Baektonggajeodamjep Tang and Senggangsasim Tang. Furthermore it should be changed into two ryangs that are one ryang dose of 'Coptidis Rhizoma' of Sohamhyung Tang, 'Ginger' of Dowha Tang, 'Ginseng Radix' of Whubaksenggangbanhagamchoinsam Tang, 'Polyporus, Poria Sclerotium, Alismatis Rhizoma, Talcum and Asini Corii Colla' of Jeoryeong Tang, 'Cimicifugae Rhizoma, Atractylodis Rhizoma Alba and Anemarrhenae Rhizoma' of Mahuangshengma Tang and 'Cassiae Cortex Interior' of Gyejigamchoryonggolmoryeo Tang. Conclusions : These results suggest that one ryang of thirteen medicinal medica such as Haematitum or Ginger of eleven decoctions such as Seonbokdaeja Tang or Bujageongang Tang should be changed into two or three ryangs.

• Nuclear Engineering and Technology
• /
• v.52 no.9
• /
• pp.2085-2091
• /
• 2020

The license for Kori-1, the first commercial reactor in Busan, Korea, was terminated in June 2017; therefore, preparations are being made for its decommissioning. Because the radioactivity of Bio-shield varies greatly throughout the structure, the doses received by the workers depend on the location, order, and duration of dismantling operations. Thus, a model for evaluating the worker external dose during the dismantling of the Kori-1 bio-shield was developed, and work scenarios for dose assessment were designed. The Dose evaluation code VISIPLAN was used for dose assessment. The dose rate around the bio-shield was evaluated and the level of exposure to the operator was evaluated according to the work scenario. The maximum annual external dose was calculated as 746.86 mSv for a diamond wire saw operator under dry cutting conditions, indicating that appropriate protective measures, such as changing dismantling sequence, remote monitoring, shield installation, and adjustment of work team are necessary for the safe dismantling of the bio-shield. Through these protective measures, it was found that the worker's dose could be below the dose limit.

• Proceedings of the KIEE Conference
• /
• 2004.11c
• /
• pp.319-321
• /
• 2004

The average glandular dose (AGD) is determined by the breast entrance skin exposure, x-ray tube target material, beam quality (half-value layer), breast thickness, and breast composition. Almost breast cancer always arises in glandular breast tissue. As a result, the average radiation absorbed dose to glandular tissue is the preferred measure of the radiation risk associated with mammography. If the normalized average glandular dose is known, the average glandular dose can be computed from the product of the normalized average glandular dose and breast entrance skin exposure. In this study, AGD was calculated by the breast thickness and various x-ray energy (HVL) in 50% glandular 50% adipose breast by Mo.-Rh. assembly. AGD is 84 mrad in compressed 5 cm breast. These results show that as increasing the breast thickness, dose also increases. But as increasing the x-ray tube voltage, dose decreases because of high penetrating ratio through the object. But high tube voltage is reducing the subject contrast. From this result, we have to consider the trade-off between subject contrast of image and dose to the patient and choose proper x-ray energy range.

• Journal of radiological science and technology
• /
• v.41 no.5
• /
• pp.445-450
• /
• 2018

We aim to evaluate safety of radiation by measuring leakage dose and patient(phantom) incident dose of ZEN-PX II dental portable equipment developed by G company. Measurement for leakage dose of equipment is conducted on the top, at the bottom, on the left, on the right and at the back. Dose measurement incident on the subject with the area dosimeter when using the phantom and measurement the leakage dose of equipment when using the phantom are evaluated. Comparing the right with the highest leakage dose as a 0 cm, 25 cm, 50 cm, 75 cm and 100 cm dose measurement at the measurement height of 100 cm, 64.2 uR was reduced to 47.3 uR in the senser mode 0.32sec. Even in film mode it was measured at 414.4 uR and about 27% lower at 162.6 uR. As the result of this study, when the irradiation time is 2 sec the right side dose is 290.5 uR and sensor mode is 0.32 sec the right side dose is 64.2 uR.

• Environmental Mutagens and Carcinogens
• /
• v.22 no.2
• /
• pp.97-105
• /
• 2002

Nowadays a huge variety of products that aim to assist to quit smoking or reduce addictive symptoms are developed and manufactured with safety evaluation, but the safety of the most recent products of interest which do not contain tobacco and nicotine, and shape cigarettes is not evaluated and guaranteed relatively. This study was carried out to evaluate the single and repeated dose inhalation toxicity and genotoxicity of H menthol (Nicotine free-tobacco free) herbal cigarettes provided by Cigastop Ltd. in ICR mice. In this study, doses which we determined to expose to mice were 40 cigarettes for 6 hours a day to mice in single dose and 20 (high dose), 10 (middle dose) and 5 cigarettes (low dose) a day for 28 days in repeated dose inhalation toxicity, in vivo chromosome aberration test and micronucleus test. The particulate substances from H menthol herbal cigarettes also were gathered and used in the Salmonella typhimurium/microsome assay (Salmonella test; Ames test). We could find neither significant changes between control and treatment groups nor dose-response effects of test material at all except serum Ca level of female middle dose treatment group in repeated dose inhalation toxicity test. In conclusion, H menthol herbal cigarettes, when applied clinically intended dose we used, might not show any toxic and/or mutagenic effect.

• Toxicological Research
• /
• v.19 no.1
• /
• pp.51-66
• /
• 2003

This study was performed to evaluate single and repeated-dose toxicities of Bee Venom Extracts (F1, F3) in Spraque-Dawley. F1 was injected subcutaneously to rat at dose levels of 0, 0.0002, 0.002, 0.02 mg/kg/day for single-dose toxicity study and repeated-dose toxicity study. F3 was injected subcutaneously to rat at dose level of 0, 0.003, 0.03, 0.3 mg/kg/day for single-dose toxicity study and repeated-dose toxicity study. In both studies, there were no dose related changes in mortality, clinical sign, body weight change, food and water consumption, opthalmoscopy, organ weights, urine analysis, biochemical examination, and hematological findings of all animals treated with Bee Venom (F1, F3). Gross and histopathological findings revealed no evidence of specific toxicity related to Bee Venom (F1, F3). These results suggest that the subcutaneous NOEL (No Observed Effect Level) of Bee Venom (F1, F3) may be over F1 -0.02 mg/kg, F3-0.3 mg/kg.

• Clinical and Experimental Reproductive Medicine
• /
• v.28 no.1
• /
• pp.47-53
• /
• 2001

Objective: This study is to investigate the clinical efficacy of low-dose FSH regimen, comparing with clomiphene citrate and human menopausal gonadotropin (CC/hMG) regimen. Methods: Retrospective study of the ovulatory factor infertility 39 patients who had been treated by intrauterine insemination (IUI). The 31 cycles of 21 patients were stimulated by CC/hMG regimen, the 22 cycles of 18 patients were stimulated by low-dose FSH regimen. We compared the rate of clinical pregnancy, multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) of both group. Results: The rate of clinical pregnancy of the CC/hMG group was 25.7% per cycle, and that of the low-dose FSH group was 54.5% per cycle. The low-dose FSH group showed a higher rate of clinical pregnancy per cycle than CC/hMG group (p=0.028). However, no differences was found statistically in the rate of multiple pregnancy and OHSS between CC/hMG group (22.2%, 5.7%) and low-dose FSH group (33.3%, 13.6%). Conclusion: This study showed that the low-dose FSH regimen is superior to CC/hMG regimen in getting clinical pregnancy, but dose not reduce the ovulation induction complications.